Children’s Panadol is back
September 25, 2013
GLAXOSMITHKLINE today
confirmed the return of Children’s
Panadol 1-5 Years Suspension
to pharmacy shelves, after the
Federal Court removed a temporary
injunction which prevented GSK
from selling the product due to
allegations of patent infringement.
A case brought by Reckitt
Benckiser, the makers of Nurofen
for Children (PD 07 Jun) claimed
that the “liquid dispensing
apparatus” syringe-based dosing
system on the GSK product violated
its patent.
The injunction restrained GSK
from marketing and selling
the Children’s Panadol 1-5
years product pending a final
determination of the matter.
In a statement released this
morning, GSK said the new ruling
has paved the way for the return
of the product “which features an
easy to use syringe to administer
the right amount of medicine
without making a mess”.
General manager of GSK
Consumer Healthcare, Vincent
Cotard, said that while the
product has been off the shelves
the company has received an
“unprecedented number of calls
from worried parents that the pain
reliever that they are familiar with
was not available.
“The level of consumer concern
reminded GSK how valuable
Children’s Panadol is to Australian
parents,” he said.
GlaxoSmithKline is now working
to ensure that the full Children’s
Panadol range is available as soon
as possible.
“We hope the return of the
product to the pharmacy shelf
wil alleviate any worries of our
concerned customers.
“Children’s Panadol is an icon of
the Australian medicine cabinet and
has been trusted by generations to
provide fast, effective and gentle
pain relief for little ones from as
young as one month,” Cotard said.
The above article was sent to subscribers in Pharmacy Daily's issue from 25 Sep 13To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 Sep 13
